Skip to main content

Advertisement

Table 1 Clinical features of 59 AML patients

From: Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients

Characteristic Number (%)
Demographics
 Median age in years a 55 (49–68)
 Male 31 (52.5)
 Female 28 (47.5)
 Median days on study 28 (25–35)
 Median number of oral samples 8 (6–9)
 Median number of stool samples 6 (4–8)
Chemotherapy
 Hypomethylatorsb 14 (23.7)
 Non-fludarabine high intensityc 19 (32.2)
 Fludarabine-containingd 19 (32.2)
 Othere 7 (11.8)
Chemotherapeutic response
 Complete remission after IC 20 (33.8)
 Overall response ratef 43 (72.8)
Infectionsg
 Microbiologically documented infection 15 (25.4)
 Clinically documented infection 14 (23.7)
 No infection 30 (50.8)
Antimicrobial administration
 Received treatment antibioticsh 53 (89.8)
  Carbapenem >72 h 39 (66.1)
  Piperacillin/tazobactam >72 h 14 (23.7)
  Cefepime >72 h 26 (44.1)
 Received prophylactic antibiotics 59 (100)
 Median number of antibiotics administered 6 (4–7)
 Median number of days exposed to all antibioticsi 28 (24–35)
 Median number of days exposed to treatment antibiotics 16 (9–24)
 Median number of days exposed to prophylactic antibiotics 16 (8–28)
  1. a All median values in this table have the interquartile range in parentheses
  2. b These chemotherapies included: 1) vasoroxin in combination with decitabine; 2) decitabine alone; 3) azacytidine in combination with pracinostat; 4) azacytidine in combination with quidartinib; and 5) SGI-110
  3. c These chemotherapies included: 1) CIA, 2) CLIA, 3) or CIA + sorafanib
  4. d These chemotherapies included: 1) FLAG-Ida or 2) FIA regimens
  5. eOther chemotherapies included:1) omacetaxine in combination with low-dose cytarabine or 2) Clad + LDAC
  6. f Includes CR (morphologic complete remission), CRi (morphologic complete remission with incomplete bloodcount recovery), and CRp (morphologic complete remission with incomplete platelet recovery)
  7. g Specific information on microbiologically and clinically documented infections can be found in the “Methods”
  8. h Refers to any antibiotic/antimicrobial-based therapy given for suspected or proven infection, that is, not included as prophylaxis (cephalosporins or fluoroquinilones). Denoted are the three most common broad spectrum antibiotics given in the study. Note that numbers of individual antibiotics add up to >100% because some patients received more than one of the listed antimicrobials during IC
  9. i Includes prophylactic antibiotics